Similarly, anti-CSF-1R (colony-stimulating factor 1 receptor) treatment with Pexidartinib (PLX3397) specifically decreased M2 tumor-promoting macrophages (Pyonteck et al., 2013), without benefitting GBM patients (Butowski et al., 2016). The gene discussed is CSF1R; the disease is neoplasm.